Foghorn Therapeutics Delivers 2nd Quarter 2021 Company Update

— Very first Sufferers Dosed in Stage 1 Medical Trials of FHD-286, an Inhibitor of BRG1/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML)

— IND Clearance for FHD-609 Received Web pages for Stage 1 Examine in Synovial Sarcoma Initiated

— Ongoing Advancement of Broad Therapeutic Pipeline that Features Protein Degraders, Enzymatic Inhibitors and Transcription Component Disruptors Targeting the Chromatin Regulatory System

CAMBRIDGE, Mass., Aug. 10, 2021 (Globe NEWSWIRE) — Foghorn Therapeutics Inc. (Nasdaq: FHTX), a medical phase biotechnology company revolutionary a new course of medications that modulate gene expression by way of selectively focusing on the chromatin regulatory process, nowadays presented a company update in conjunction with the Company’s From 10-Q submitting for the quarter ended June 30, 2021. With an first focus in oncology, Foghorn’s Gene Traffic Regulate Platform® and ensuing broad pipeline has the potential to renovate the life of persons suffering from a extensive spectrum of health conditions.

“We proceed to make reliable development advancing our two to start with-in-class medical packages to arise from our proprietary Gene Website traffic Manage Platform,” mentioned Adrian Gottschalk, President and Chief Government Officer. “We anticipate acquiring preliminary stage I details of FHD-286, our selective, oral inhibitor of BRG1/BRM in metastatic uveal melanoma and relapsed or refractory AML and myelodysplastic syndromes (MDS), as early as the fourth quarter of 2021, and section I information of FHD-609, our first protein degrader medical candidate, for the treatment of synovial sarcoma as early as the initial half of 2022.”

Continued Mr. Gottschalk, “Beyond these two clinical applications, we keep on to broaden our robust pipeline of precision therapeutic candidates targeting distinct facets of the chromatin regulatory method, together with our protein degrader applications and platform, including FHD-609, our BRM-selective degrader, ARID1B protein degrader and other undisclosed packages.”

Current Corporate Highlights:

Dosed Initial Client with FHD-286. In Might 2021, Foghorn declared the dosing of the to start with client in its initial-in-human medical demo of FHD-286, an inhibitor of BRG1/BRM, in metastatic uveal melanoma and relapsed or refractory AML and MDS, spots of higher unmet medical will need. This is Foghorn’s initial drug applicant to enter the clinic and the initially of a new course of therapeutics right focusing on the chromatin regulatory procedure. To understand additional about these studies be sure to pay a visit to ClinicalTrials.gov. (Hyperlink here for metastatic uveal melanoma and here for AML and MDS)
Been given investigational new drug application (IND) clearance for FHD-609. Foghorn received Fda clearance of its IND application for FHD-609. FHD-609 is a extremely strong, selective, intravenous, smaller molecule protein degrader of BRD9, originally staying created for the treatment of synovial sarcoma with the intention to broaden into supplemental indications, like SMARCB1 deleted tumors. Web-sites for the period 1 review have been initiated and are at the moment screening people. To find out far more about this review, please check out ClinicalTrials.gov.
BRM Selective Inhibitor Plan State-of-the-art to Lead Optimization. Details introduced in the course of Foghorn’s 2021 Investigation & Development Webinar shown strong tumor expansion inhibition with the Company’s BRM-selective inhibitor. The program has highly developed into lead optimization with an IND planned for 2022.
Participation at AACR 2021. In April 2021, Foghorn presented a poster titled “Discovery of novel BAF inhibitors for the procedure of transcription issue-pushed cancers” (Link to poster here) and chaired a panel at the American Affiliation for Most cancers Study (AACR) Once-a-year Assembly 2021. Vital highlights of the details introduced provided a novel collection of compounds identified and created by Foghorn that potently and selectively inhibit the ATPase components of the BAF intricate, BRG1 and BRM. These preclinical info delivered the foundation for 1st-in-human scientific tests of BAF ATPase inhibition as a novel therapeutic to take care of uveal melanoma.
Appointed Ian Smith to Board of Directors. On April 27^th, 2021, Foghorn appointed Ian Smith to its Board of Directors, incorporating a assorted skill set spanning many years as a demonstrated biotechnology chief. The addition of Ian to the Board delivers substantial organization progress and cash formation know-how to Foghorn.
Held 1st Exploration and Advancement Day Webinar. On June 15^th, 2021, Foghorn held its inaugural Analysis and Advancement Day Webinar showcasing presentations from key feeling leaders and the Foghorn management group highlighting the biological great importance of the chromatin regulatory process in gene expression and human disease and its wide applicability in precision oncology. The replay can be accessed right here.

Crucial Impending Milestones:

FHD-286 information. Foghorn expects initial data from the Company’s section 1 research of FHD-286 in both of those metastatic uveal melanoma and relapsed/refractory AML and MDS as early as the fourth quarter of 2021.
FHD-609 facts. Foghorn expects original details from the Company’s section 1 review in synovial sarcoma as early as the 1st 50 percent of 2022.

Forthcoming Functions

The Wedbush PacGrow Health care Virtual Meeting, panel dialogue, “Bullseye – Qualified Oncology Section 2,” Wednesday, August 11 at 10:20 a.m. ET. The webcast can be accessed right here.
The Morgan Stanley Worldwide Health care Conference, September 13-15, 2021.

Monetary Situation

Foghorn documented income, hard cash equivalents and marketable securities of $141.3 million as of June 30, 2021, as compared to $160.9 million as of March 31, 2021, and $185.8 million as of December 31, 2020.

About Foghorn Therapeutics

Foghorn® Therapeutics is getting and establishing a novel course of medicines focusing on genetically determined dependencies inside of the chromatin regulatory system. By means of its proprietary scalable Gene Targeted traffic Control® system, Foghorn is systematically studying, figuring out and validating potential drug targets inside of the chromatin regulatory procedure. The organization is creating numerous merchandise candidates in oncology.

Forward-Searching Statements

This push release incorporates “forward-searching statements” relating to the Company’s clinical packages for FHD-286 and FHD-609 and the Company’s investigation pipeline. Forward-seeking statements involve statements regarding the Company’s scientific demo, item candidates and investigate endeavours and other statements discovered by words and phrases this sort of as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future durations. Ahead-looking statements are based on our present-day anticipations and assumptions regarding funds industry situations, our business, the financial system and other potential situations. Mainly because ahead-hunting statements relate to the foreseeable future, by their mother nature, they are subject matter to inherent uncertainties, hazards and variations in circumstances that are complicated to forecast. As a final result, precise final results may differ materially from these contemplated by the forward-searching statements. Significant elements that could induce genuine effects to differ materially from all those in the ahead-hunting statements contain regional, nationwide or world wide political, economic, company, competitive, marketplace and regulatory conditions, such as hazard with regards to the timing of filing an IND for our merchandise candidates and other components established forth beneath the heading “Risk Factors” in the Company’s Type 10-K. Any ahead-on the lookout assertion manufactured in this press release speaks only as of the date on which it is built.

Media Call:

Fanny Cavalié, Foghorn Therapeutics Inc.
[email protected]

Gregory Kelley, Ogilvy
[email protected]

Trader Relations Contact:

Ben Strain, Foghorn Therapeutics Inc.
[email protected]

Hans Vitzthum, LifeSci Advisors
617-430-7578
[email protected]